Table 1.
Clinicopathological features of pancreatic carcinoma n (%)
| Data | Vimentin methylated negative group (n = 43)2 | Vimentin methylated positive group (n = 21)3 | P value |
| Sex | 0.582 | ||
| Male | 27 (62.8) | 15 (71.4) | |
| Female | 16 (37.2) | 6 (28.6) | |
| Tumor position | 0.007 | ||
| Head | 11 (25.6) | 13 (61.9) | |
| Body and tail | 32 (74.4) | 8 (38.1) | |
| Preoperative CEA level | 0.294 | ||
| Normal | 20 (46.5) | 13 (61.9) | |
| Elevated | 23 (53.5) | 8 (38.1) | |
| Preoperative CA19-9 level | 0.600 | ||
| Normal | 24 (55.8) | 10 (47.6) | |
| Elevated | 19 (44.2) | 11 (52.4) | |
| Pathological N staging1 | 0.426 | ||
| N0 | 21(48.8) | 13 (61.9) | |
| N1 | 22 (51.2) | 8 (38.1) | |
| Pathological T staging1 | 0.753 | ||
| T1 | 14 (32.6) | 5 (23.8) | |
| T2 | 19 (44.2) | 11 (52.4) | |
| T3 | 10 (23.3) | 5 (23.8) | |
| Adjuvant chemotherapy | 0.791 | ||
| No | 20 (46.5) | 11 (52.4) | |
| Yes | 23 (53.5) | 10 (47.6) | |
1
The pathological T and N staging was based on the UICC staging systems for pancreatic cancer;
2
Median age 54 years, range: 36-71 years;
3
Median age 53 years, range: 41-68 years.